Ontology highlight
ABSTRACT: Objectives
To report the attitudes and opinions of subjects in US clinical trials about whether or not, and why, they should receive post-trial access (PTA) to the trial drug, care and information.Design
Focus groups, short self-administered questionnaires.Setting
Boston, Dallas, Detroit, Oklahoma City.Participants
Current and recent subjects in clinical trials, primarily for chronic diseases.Results
93 individuals participated in 10 focus groups. Many thought researchers, sponsors, health insurers and others share obligations to facilitate PTA to the trial drug, if it benefited the subject, or to a therapeutic equivalent. Some thought PTA obligations include providing transition care (referrals to non-trial physicians or other trials, limited follow
SUBMITTER: Sofaer N
PROVIDER: S-EPMC3044680 | biostudies-literature | 2009 Mar
REPOSITORIES: biostudies-literature